Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

・Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...

Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions ...

・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...

Minecraft remains one of the best games of all time over a decade on from its release, but spending such a long time in one game could lead to you running out of ideas. We've been there: you've ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...